دورية أكاديمية

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
المؤلفون: Adams, Atoya, Andrews, Jane M, Behrend, Clint E, Brown, Gregor J E, Chen Yi Mei, Swee Lin, Coates, Allan G, DiMarino, Anthony J, Ee, Hooi, Elliott, David E, Epstein, Roger M, Feyen, Bryan John, Fogel, Ronald P, Friedenberg, Keith Alan, Gearry, Richard B, Gerdis, Michael S, Goldstein, Michael J, Gupta, Vipin K, Holmes, Robert John, Holtmann, Gerald J, Idarraga, Samuel H, James, George W, King, Tim, Klein, Terry D, Kupfer, Sonia S, Lebwohl, Benjamin, Lowe, Matthew John, Murray, Joseph A, Newton, Eric B, Quinn, Dean, Radin, David M, Ritter, Timothy E, Stacey, Helen Lee, Strout, Cynthia B, Stubbs, Richard S, Thackwray, Susan Lynn, Trivedi, Vivek M, Weber, John R, Wilson, Scott A, Tye-Din, Jason A, Daveson, A James M, Goel, Gautam, Goldstein, Kaela E, Hand, Holly L, Neff, Kristin M, Popp, Alina, Taavela, Juha, Maki, Markku, Isola, Jorma, Williams, Leslie J, Truitt, Kenneth E, Anderson, Robert P *
المصدر: In The Lancet Gastroenterology & Hepatology May 2023 8(5):446-457
قاعدة البيانات: ScienceDirect
الوصف
تدمد:24681253
DOI:10.1016/S2468-1253(22)00428-9